Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

KMDABullishEarningsShort Term

High materiality8/10

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

StockNews.AIAug 12, 7:05 AM EDT1 source

Trading thesisImportance 8/10

KMDA's stock could rally near-term on solid results and a visible $50M contract; monitor Q4 execution and guidance progression over the next 1–3 quarters.

AI summary

What happened and why it matters

Kamada posted record first half 2026 results with $100.2 million in revenue and $25.7 million in adjusted EBITDA, reaffirming its full-year target of $200–$205 million in revenue and $50–$53 million in EBITDA. The company also secured a three-year, roughly $50 million plasma supply agreement, with initial sales expected in Q4 2026, signaling sharper growth in the back half. A ramp in Texas plasma collection and M&A/distribution expansion further support long-term profitability.

New $50M, 3-year plasma supply deal adds near-term revenue visibility.
Guidance reaffirmation reduces execution risk and supports multiple expansion.
Texas plasma-collection ramp could lift future sales cadence.
Israel/MENA distribution expansion broadens addressable market.

Sentiment rationale

Strong H1 results and guidance confidence reduce downside risk; the ~$50M plasma deal adds revenue visibility and could drive multiple expansion if Q4 execution aligns with guidance. Risks include macro/regulatory shifts, execution delays on new agreements, and competition in plasma-derived therapies, which could cap upside.

Key facts

01
H1 2026 revenue $100.2M, up 13% YoY; AdjustedEBITDA $25.7M, 26% margin.
02
Q2 2026 revenue $54.9M, up 23% YoY; Adjusted EBITDA $14.1M, 26% margin.
03
Kamada reaffirms 2026 guidance: $200–$205M revenue; $50–$53M Adjusted EBITDA.
04
Announces three-year plasma sales agreement (~$50M); initial Q4 2026 sales expected.
05
H1 operating cash flow $17.8M; cash position $70.1M; dividend paid $14.4M.

Earnings

Category Type: Earnings. The release centers on Kamada’s quarterly and half-year results, reaffirmed full-year guidance, and a material new sales contract, all of which are core earnings catalysts influencing valuation and forward expectations.